Latest Breaking News On - Roivant sciences forward - Page 1 : comparemela.com

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, June 28, 2023, to report its fina.

United statesCity ofUnited kingdomStephanie leeSecurities exchangeRoivant sciencesRoivant sciences forwardExchange commissionRoivant sciences nasdaqSecurities actSecurities exchange actRisk factors

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31,

BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 26, 2023 (GLOBE NEWSWIRE) Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live conference call and

United statesCity ofUnited kingdomStephanie leeSecurities exchangeRoivant sciences forwardRoivant sciences nasdaqRoivant sciencesExchange commissionSecurities actSecurities exchange actRisk factors

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis

Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomUnited statesStephanie leeRoivant sciences forwardRoivant sciences nasdaqSecurities exchangeRoivant sciencesExchange commissionSecurities actSecurities exchange actRisk factors

Roivant Sciences (ROIV) Reports Chronic Period Data for RVT-3101

Roivant Sciences (ROIV) Reports Chronic Period Data for RVT-3101
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Matt glineStephanie leeExchange commissionSecurities exchangeRoivant sciencesRoivant sciences forwardRoivant sciences nasdaqClinical remissionEndoscopic improvementEndoscopic remissionSecurities actSecurities exchange actRisk factors

Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period

This is the first-ever long-duration data reported for an anti-TL1A antibodyAt the expected Phase 3 once-monthly subcutaneous dose in the overall population, RVT-3101 treatment resulted in improved Clinical Remission1 (36% at week 56 vs. 29% at week 14) a.

United statesCity ofUnited kingdomMatt glineStephanie leeRoivant sciences nasdaqRoivant sciences forwardRoivant sciencesExchange commissionSecurities exchangeClinical remissionEndoscopic improvementEndoscopic remissionSecurities actSecurities exchange actRisk factors